Cramer, Daniel

Email:	dcramer@partners.org
Fax:	(617) 732-4899
DMCC Person ID:	995
EDRN Title:	EDRN Associate Member
Specialty:	None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name	Biomarkers	Datasets
Pre-operative plevic mass study	0	0

Closed Protocols

Protocol Name	Biomarkers	Datasets
Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer	0	0
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement	28	0
Biomarker Reference Sets for Cancers in Women	0	0
EDRN Resource Network Exchange	0	0
Ovarian Cancer Screening Pilot Trial In High Risk Women	0	0
PLCO Ovarian Phase III Validation Study	50	1
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study	55	2

Publications

Publication Name	PubMed ID	Journal
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.	18349277	Cancer Epidemiol. Biomarkers Prev.
Blood and urine markers for ovarian cancer: a comprehensive review.	15322314	Dis. Markers
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.	15894662	Cancer Epidemiol. Biomarkers Prev.
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.	12912935	Clin. Cancer Res.
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.	14581349	Clin. Cancer Res.
Non-genomic biomarkers of risk in ovarian cancer.	18057519	Dis. Markers
Osteopontin as a potential diagnostic biomarker for ovarian cancer.	11926891	JAMA
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.	15161704	Clin. Cancer Res.
Pooling of case specimens to create standard serum sets for screening cancer biomarkers.	17301268	Cancer Epidemiol. Biomarkers Prev.
Promoter hypermethylation profile of ovarian epithelial neoplasms.	16061849	Clin. Cancer Res.
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.	11584061	J. Natl. Cancer Inst.
Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer.	17245808	J Bioinform Comput Biol
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.	16428483	Clin. Cancer Res.
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study.	19008269	BMJ
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).	19282241	Lancet Oncol.
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.	18061248	Gynecol. Oncol.
Urokinase-type plasminogen activator receptor: a beacon of malignancy?	18794069	Clin. Cancer Res.
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.	18245537	Clin. Cancer Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.